REZUROCK Sales Forecast, and Market Size Analysis - 2034

Key Factors Driving REZUROCK Growth

• Strong uptake as a standard-of-care therapy in chronic GvHD

REZUROCK, a selective ROCK2 (Rho-associated coiled-coil kinase 2) inhibitor, has become an established treatment for chronic graft-versus-host disease (cGvHD) in patients who have failed at least two prior lines of systemic therapy. Its differentiated mechanism modulates inflammatory and fibrotic pathways while restoring immune balance, addressing a significant unmet need in refractory cGvHD. Sanofi states that REZUROCK has become the standard of care in the indicated setting across launched markets, supported by growing physician experience and favorable real-world outcomes.

• Robust commercial growth driven by expanding global adoption

REZUROCK continues to demonstrate strong commercial performance. According to Sanofi's 2025 Annual Report, global REZUROCK sales reached €490 million in 2025, representing an 8.7% increase at constant exchange rates (CER) over 2024. Growth was driven by continued expansion in the United States, where sales reached €425 million, as well as rapid uptake in international markets, particularly China, following National Reimbursement Drug List (NRDL) inclusion. Since launch, more than 20,000 patients worldwide have received REZUROCK through commercial, early access, or managed access programs.

• Geographic expansion significantly enlarges the addressable market

International regulatory approvals continue to expand REZUROCK's commercial opportunity. By the end of 2025, the product had been approved in 20 countries, with commercial launches in Japan, South Korea, Thailand, China, Canada, the UK, and other markets. In March 2026, the European Commission granted conditional marketing authorization for REZUROCK for adults and adolescents with chronic GvHD, opening an important new market where few effective therapies are available. Continued geographic expansion is expected to remain a major contributor to future revenue growth.

• Favorable efficacy, tolerability, and convenient oral administration support physician adoption

REZUROCK's growth is supported by durable efficacy demonstrated in the ROCKstar Phase II trial and by accumulating real-world evidence. Clinical studies have shown high overall response rates, durable responses lasting beyond one year in many patients, and clinically meaningful improvements across multiple affected organs. Its once-daily oral administration, combined with a generally manageable safety profile, offers an important advantage over more complex immunosuppressive regimens and contributes to increasing physician preference. These factors have been highlighted by Sanofi as key drivers of continued patient uptake.

• Lifecycle management through additional indications provides long-term growth opportunities

Beyond chronic GvHD, Sanofi is pursuing lifecycle expansion to broaden REZUROCK's clinical utility. The company is developing an oral suspension formulation to support pediatric use and is conducting the Phase III ROCKaspire trial evaluating belumosudil for chronic lung allograft dysfunction (CLAD) following bilateral lung transplantation. Although the Phase III ROCKnrol-1 study in newly diagnosed chronic GvHD was discontinued after a futility analysis, successful expansion into CLAD or other fibrotic immune-mediated disorders could substantially increase the product's long-term commercial potential.

REZUROCK Recent Developments

In March 2026, The European Commission granted a conditional marketing authorisation for Rezurock (belumosudil) for the treatment of chronic graft-versus-host disease (GVHD) in adults and in children aged 12 years and older with a body weight of at least 40 kg. The medicine is to be used when other treatment options provide limited clinical benefit, are not suitable, or have been exhausted. The conditional marketing authorisation is contingent on completion of a confirmatory, randomised, controlled study.

“REZUROCK Sales Forecast, and Market Size Analysis - 2034” report provides comprehensive insights of REZUROCK for approved indication like Graft-versus-host disease and Lung transplant rejection; as well as potential indication like Idiopathic pulmonary fibrosis, Systemic scleroderma, Autoimmune disorders, and Multiple myeloma in the 7MM. A detailed picture of REZUROCK’s existing usage in approved and anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 -2034 is provided in this report along with a detailed description of the REZUROCK for approved and potential indications. The REZUROCK market report provides insights about REZUROCK’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current REZUROCK performance, future market assessments inclusive of the REZUROCK market forecast analysis for approved and potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of REZUROCK sales forecasts, along with factors driving its market.

REZUROCK Drug Summary

REZUROCK (Belumosudil) is an oral, selective Rho-associated coiled-coil kinase 2 (ROCK2) inhibitor developed by Sanofi (originally developed by Kadmon, now part of Sanofi) for the treatment of chronic graft-versus-host disease (cGVHD). Belumosudil selectively inhibits ROCK2, thereby modulating pro-inflammatory immune responses by reducing Th17 and follicular helper T-cell activity while promoting the expansion and function of regulatory T cells (Tregs). In addition, ROCK2 inhibition decreases profibrotic signaling, making the drug particularly effective in managing both inflammatory and fibrotic manifestations of cGVHD. REZUROCK is administered orally once daily and is approved for adult and pediatric patients aged 12 years and older with cGVHD after failure of at least two prior lines of systemic therapy. Clinical studies, including the pivotal ROCKstar trial, demonstrated high overall response rates, durable responses across multiple affected organs, meaningful symptom improvement, and a favorable safety profile, establishing REZUROCK as an important targeted treatment option for patients with refractory chronic GVHD. The report provides REZUROCK’s sales, growth barriers and drivers, post usage and approvals in multiple indications. 

Scope of the REZUROCK Market Report

The report provides insights into:

• A comprehensive product overview including the REZUROCK MoA, description, dosage and administration, research and development activities in approved indications like Graft-versus-host disease and Lung transplant rejection; as well as potential indication like Idiopathic pulmonary fibrosis, Systemic scleroderma, Autoimmune disorders, and Multiple myeloma.
• Elaborated details on REZUROCK regulatory milestones and other development activities have been provided in REZUROCK market report.
• The report also highlights REZUROCK‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in approved and potential indications across the United States, Europe, and Japan.
• The REZUROCK market report also covers the patents information, generic entry and impact on cost cut.
• The REZUROCK market report contains current and forecasted REZUROCK sales for approved and potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The REZUROCK market report also features the SWOT analysis with analyst views for REZUROCK in approved and potential indications.

Methodology

The REZUROCK market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by the team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.

REZUROCK Analytical Perspective

• In-depth REZUROCK Market Assessment

This REZUROCK sales market forecast report provides a detailed market assessment of REZUROCK for approved indication like Graft-versus-host disease and Lung transplant rejection; as well as potential indication like Idiopathic pulmonary fibrosis, Systemic scleroderma, Autoimmune disorders, and Multiple myeloma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted REZUROCK sales data uptil 2034.

• REZUROCK Clinical Assessment

The REZUROCK market report provides the clinical trials information of REZUROCK for approved and potential indications covering trial interventions, trial conditions, trial status, start and completion dates.

REZUROCK Competitive Landscape

The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.

REZUROCK Market Potential & Revenue Forecast

• Projected market size for the REZUROCK and its key indications
• Estimated REZUROCK sales potential (REZUROCK peak sales forecasts)
• REZUROCK Pricing strategies and reimbursement landscape

REZUROCK Competitive Intelligence

• Number of competing drugs in development (pipeline analysis)
• REZUROCK Market positioning compared to existing treatments
• REZUROCK Strengths & weaknesses relative to competitors

REZUROCK Regulatory & Commercial Milestones

• REZUROCK Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity

REZUROCK Clinical Differentiation

• REZUROCK Efficacy & safety advantages over existing drugs
• REZUROCK Unique selling points  

REZUROCK Market Report Highlights

• In the coming years, the REZUROCK market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The REZUROCK companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence REZUROCK’s dominance.
• Other emerging products for Graft-versus-host disease and Lung transplant rejection; as well as potential indication like Idiopathic pulmonary fibrosis, Systemic scleroderma, Autoimmune disorders, and Multiple myeloma are expected to give tough market competition to REZUROCK and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of REZUROCK in approved and potential indications.
• Analyse REZUROCK cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted REZUROCK sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of REZUROCK in approved and potential indications.

Key Questions

• What is the class of therapy, route of administration and mechanism of action of REZUROCK? How strong is REZUROCK’s clinical and commercial performance?
• What is REZUROCK’s clinical trial status in each individual indications such as Graft-versus-host disease and Lung transplant rejection; as well as potential indication like Idiopathic pulmonary fibrosis, Systemic scleroderma, Autoimmune disorders, and Multiple myeloma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the REZUROCK Manufacturers?
• What are the key designations that have been granted to REZUROCK for approved and potential indications? How are they going to impact REZUROCK’s penetration in various geographies?
• What is the current and forecasted REZUROCK market scenario for approved and potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of REZUROCK in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to REZUROCK for approved and potential indications?
• Which are the late-stage emerging therapies under development for the treatment of approved and potential indications?
• How cost-effective is REZUROCK? What is the duration of therapy and what are the geographical variations in cost per patient?

This product will be delivered within 2 business days.